Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


R&D In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Motavizumab reduced hospitalization in Phase III trial: MedImmune's motavizumab reduced hospitalizations due to respiratory syncytial virus by 83 percent compared to placebo in a Phase III trial, the firm says May 4. The monoclonal antibody is being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. The trial showed a 71 percent reduction in the incidence of RSV-specific lower respiratory infections requiring outpatient management, which was the study's secondary endpoint. The randomized, double-blind study involved 1,410 full-term healthy infants less than six months old in certain Southwest Native American populations and was designed to compare monthly intramuscular injections of motavizumab against placebo. The study confirmed what previous epidemiological studies have shown: that these populations have high rates of hospitalization due to RSV. Motavizumab would be a follow-on to AstraZeneca's Synagis (palivizumab)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts